ABVX

Abivax SA is a French clinical-stage biotechnology company headquartered in Paris, focused on developing therapies for chronic inflammatory diseases.

Its lead drug candidate, Obefazimod (ABX464), is a first-in-class oral miR-124 enhancer showing promising Phase 3 results in ulcerative colitis. The company plans to seek FDA and EMA approval following successful maintenance trials.

Abivax’s pipeline also includes potential treatments for Crohn’s disease and other inflammatory disorders.